The MHRA has approved an oral semaglutide pill for weight loss — a genuine first for the UK. If you have been waiting for a needle-free alternative to Wegovy injections, this is the news you have been hoping for. Here is everything you need to know before spending a penny.
The UK’s medicines regulator has approved a daily weight loss tablet for the first time. The Wegovy pill — an oral version of the drug semaglutide — has been given the green light for adults with obesity. Private prescriptions are expected to be available within weeks.
This development was announced on 11 June 2026.
According to the MHRA (the Medicines and Healthcare products Regulatory Agency — the UK body that decides which medicines are safe to sell here), the tablet is approved for adults with a BMI of 30 or above. BMI, or body mass index, is a simple height-to-weight calculation doctors use to assess healthy weight ranges.
How Does the Wegovy Pill Actually Work?
Semaglutide is a GLP-1 receptor agonist. In plain English, it mimics a hormone your gut naturally releases after eating. That hormone tells your brain you are full and slows down how quickly your stomach empties. The injectable version of Wegovy has been available in the UK since 2023. This tablet delivers the same active ingredient — just without the needle.
According to Novo Nordisk, the Danish company that makes Wegovy, the tablet comes in four doses: 1.5mg, 4mg, 9mg and 25mg. Patients start low and work up gradually. This step-up approach helps your body adjust and reduces the chance of nausea or stomach upset, which are the most commonly reported side effects.
According to Novo Nordisk, patients who are already stable on the 2.4mg Wegovy injection can switch directly to the 25mg daily tablet. That is a meaningful option for anyone who finds injections uncomfortable or inconvenient.
What Did the Clinical Trial Show?
The approval is backed by a large clinical trial called OASIS 4. According to data from the OASIS 4 trial, participants taking the 25mg daily dose lost an average of 16.6 percent of their body weight over 64 weeks. To put that in real terms: a woman weighing 14 stone could expect to lose roughly 2 stone 4 pounds on average.
That result places the oral tablet in a similar performance range to the injectable version, though the injection trials showed slightly higher average losses of around 15 to 17 percent depending on the study. According to the MHRA, the benefit-risk profile of the tablet was judged to be acceptable for the approved population.
It is worth noting that trial results show averages. Some people lose significantly more, and some lose less. Weight loss medication works best alongside changes to diet and activity levels.
What About NHS Access and Cost?
The Wegovy pill has not yet been assessed for NHS use. According to the MHRA, regulatory approval and NHS funding are two separate processes. The NHS body that decides funding — NICE, the National Institute for Health and Care Excellence — has not yet reviewed the oral tablet.
This means that in the short term, the tablet will only be available through private clinics and private prescriptions. Novo Nordisk has not yet confirmed UK pricing publicly. However, given that the injectable Wegovy currently costs between £150 and £250 per month privately, patients should expect a broadly similar price range for the tablet — though competition and pharmacy contracts may shift this over time.
If you are already exploring your options and want to understand the full landscape of weight loss injections currently available in the UK, our Weight Loss Jabs Guide covers everything from how these medicines work to what to expect at a private clinic.
What This Means For UK Patients
This approval is genuinely significant — but it pays to be clear-eyed about what it does and does not mean right now. The Wegovy pill is not yet available on the NHS, so anyone who wants it in the coming months will need to pay privately. That matters enormously given the cost-of-living pressures many women in this country are already navigating.
The needle-free format will be a real barrier-remover for many people. Fear of injections is one of the most commonly cited reasons women do not start or stay on GLP-1 treatment. A daily tablet removes that obstacle entirely.
However, do not rush to switch or start before speaking to a doctor. The dose equivalence between the injection and the tablet is not a simple one-to-one swap for everyone. A qualified prescriber needs to assess your individual situation. And if you are currently stable and happy on the injectable version, there may be no clinical reason to change just because something new is available. New does not automatically mean better for you specifically.
If you are new to this area entirely, our Start Here guide will give you a clear, honest foundation before you book any consultation.
Frequently Asked Questions
Is the Wegovy pill available on the NHS?
No — not yet. According to the MHRA, the tablet has received regulatory approval but has not been assessed for NHS funding. NICE would need to conduct a separate review before any NHS prescribing could begin. That process typically takes one to two years.
How much weight can I expect to lose on the oral semaglutide tablet?
According to data from the OASIS 4 trial, participants on the highest 25mg dose lost an average of 16.6 percent of their body weight over 64 weeks. Results vary between individuals, and the trial was conducted alongside dietary guidance and support.
Can I switch from the Wegovy injection to the tablet?
According to Novo Nordisk, patients who are stable on the 2.4mg injectable dose of Wegovy can switch to the 25mg daily tablet. You should only make this switch under the guidance of your prescribing doctor, who can assess whether it is appropriate for your specific situation.
What are the side effects of the Wegovy pill?
According to Novo Nordisk trial data, the most commonly reported side effects are nausea, vomiting and diarrhoea — the same side effects seen with the injectable version. These are most common during the dose-escalation phase and tend to reduce over time. Your prescriber can advise on how to manage them.
For those interested in what else is emerging in the weight loss medicine pipeline, including triple-action treatments, our Retatrutide UK Guide explains the next generation of options currently in development.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment.
Get the UK peptide medicine briefing in your inbox.
Free weekly. No spam. Unsubscribe any time.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment. Information correct at time of publication. The Peptide Brief updates articles when guidance changes.
